Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.

Fernando TorresHarrison FarberArsen RisticVallerie McLaughlinJohn AdamsJinkun ZhangPreston KlassenWilliam ShanahanJohn GrundyInes HoffmannChristopher CabellPilar Escribano-SubiasNamita SoodAnne KeoghGwyn D'SouzaLewis Rubin

Published in: The European respiratory journal (2019)

Ralinepag reduced PVR compared with placebo in PAH patients on mono (41%) or dual combination (59%) background therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
clinical trial
prognostic factors
double blind
randomized controlled trial
mesenchymal stem cells
polycyclic aromatic hydrocarbons
replacement therapy